SJEPD021_D.RNA-Seq
EPN · Posterior Fossa EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Posterior Fossa EPN
- cancer_type
- EPN
- subtype
- Posterior Fossa EPN
- age_years
- 2.01
- fusion
- other ZFTA
- e1_e2
- E2
- umap1_2d
- -6.615362063
- umap2_2d
- -0.375348177
- umap1_3d
- 1.395363487
- umap2_3d
- 3.009475889
- umap3_3d
- 0.966528391
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HYPOXIA+0.440
- ESTROGEN_RESPONSE_EARLY+0.430
- IL6_JAK_STAT3_SIGNALING+0.410
- ADIPOGENESIS+0.380
- MYOGENESIS+0.380
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.380
- COAGULATION+0.340
- COMPLEMENT+0.340
- INFLAMMATORY_RESPONSE+0.340
- KRAS_SIGNALING_DN+0.340
Top 10 suppressed
- G2M_CHECKPOINT-0.510
- E2F_TARGETS-0.480
- MITOTIC_SPINDLE-0.310
- MYC_TARGETS_V1-0.230
- DNA_REPAIR-0.220
- NOTCH_SIGNALING-0.210
- ANGIOGENESIS-0.190
- MYC_TARGETS_V2-0.160
- TGF_BETA_SIGNALING-0.110
- UV_RESPONSE_DN-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR662978 | GTEX | — | 0.868 |
| 2 | BS_NB5XWMJT | low-grade glioma | — | 0.864 |
| 3 | TCGA-21-5784-01A-01R-1635-07 | — | cohortSQ1 | 0.850 |
| 4 | SRR820518 | GTEX | — | 0.842 |
| 5 | BS_2R9TCR03 | low-grade glioma | — | 0.839 |
| 6 | SRR1487685 | GTEX | — | 0.838 |
| 7 | SRR1328487 | GTEX | — | 0.834 |
| 8 | SRR663693 | GTEX | — | 0.829 |
| 9 | BS_C51RB0YR | low-grade glioma | — | 0.824 |
| 10 | b2fa82e4-58f2-4dc6-ad6e-31886a1c9851 | — | — | 0.822 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HYPOXIA | 0.440 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.430 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.410 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.380 | Inavolisib | — uncovered |
| MYOGENESIS | 0.380 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.380 | Inavolisib | — uncovered |
| COAGULATION | 0.340 | Binimetinib | — uncovered |
| COMPLEMENT | 0.340 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.340 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.340 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.330 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.330 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.330 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.310 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.270 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.270 | Idelalisib | — uncovered |
| APOPTOSIS | 0.260 | Idelalisib | — uncovered |